CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 39 enrolled
Drug / intervention
Daunorubicin +11 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01920737
NCT01920737Phase 2Active

A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia

Memorial Sloan Kettering Cancer Center·interventional·Posted Aug 12, 2013·Updated Sep 16, 2025

In Brief

A Phase 2 clinical trial evaluating Daunorubicin, Vincristine, and 10 other interventions for Leukemia. Active but no longer recruiting, targeting 39 participants across 3 sites.

Detailed Summary

The purpose of the study is to find out whether the combination of chemotherapy drugs that are routinely used in children with ALL, will be safe and effective in treating adult patients with ALL. The standard treatment for adults with ALL consists of many chemotherapy drugs that are given in different combinations and in several steps. In adult ALL there is no standard which drugs to give and how to combine them. Some leukemias have a chromosome abnormality called Philadelphia chromosome (also called Ph Positive) and some leukemias do not (called Ph Negative). In this study we want to see whether this combination of chemotherapy drugs will be safe and effective in treating adult patients with Ph Negative ALL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States

Timeline

Phase 2Active
2014201520162017201820192020202120222023202420252026
First PostedAug 12, 2013
Enrollment StartAug 7, 2013
Primary CompletionAug 1, 2026
TodayJul 1, 2026
Enrollment to primary: 13.0 yearsPosted 12.9 years agoPrimary completion in 1 month

Interventions

Daunorubicindrug

In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.

Vincristinedrug

Prednisonedrug

PEG-Asparaginasedrug

Methotrexatedrug

6-MP (6-Mercaptopurine)drug

Cyclophosphamidedrug

Cytarabinedrug

Leucovorindrug

Dexamethasonedrug

Blood drawother

CT/PET scansdevice

PET or CT scan every 6 months for 3 years